Data investigation

Does a Lifetime of It Change Anything?

People who have carried excess weight since childhood often assume a drug will not work for them. Across 3,782 participants in three trials, obesity beginning before age 25 made no difference to the response.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

People who have carried excess weight since childhood often assume a drug will not work for them, that something about their weight is more entrenched, more constitutional, less reversible. An analysis of 3,782 participants across three trials tested that directly. Those whose obesity began before age 25 lost 23% of their body weight on tirzepatide. Those whose began later lost 22%.[1]

The comparison

Participants in SURMOUNT-1, SURMOUNT-3 and SURMOUNT-4 were divided by whether their obesity was diagnosed before or after age 25, and followed for 72 weeks. The early-onset group had lived with it for a mean of 20 years against 11.

Change at 72 weeks on tirzepatide, early-onset against later-onset obesity.[1]
MeasureEarly onsetLater onset
Body weight−23%−22%
Waist circumference−22 cm−19 cm
HbA1c−0.51%−0.52%
Triglycerides−32%−31%
Systolic blood pressure−8 mmHg−8 mmHg
Twice the duration, and no penalty on any measure.

The same pattern held across all three trials. Whatever else two decades of obesity does, it does not appear to blunt the response to this drug. That is a specific piece of reassurance for a group that is often told, or tells itself, the opposite.

The paradox at baseline, and the confounder in it

The two groups did not start in the same place, and the differences run in unexpected directions.

Baseline characteristics. All differences at P ≤ 0.004.[1]
Early onsetLater onset
Obesity duration20 ± 12 years11 ± 8 years
BMI40 ± 737 ± 6
Waist circumference118 ± 16 cm112 ± 14 cm
HbA1c5.48%5.60%
Triglycerides120 mg/dL130 mg/dL
Systolic blood pressure121 mmHg125 mmHg

The early-onset group had more adiposity on both measures, and better blood sugar, triglycerides and blood pressure. The authors describe it as a mixed metabolic profile, which it is.

There is an obvious explanation the abstract does not address: age. Someone whose obesity began before 25 is likely to be younger at enrollment than someone whose began later, and younger people have better blood pressure and lipids regardless of anything else. Whether the analysis adjusted for age is not stated, and until it is, the “paradox” may simply be an age difference.

If it survives adjustment, it would be interesting, because it would suggest that adiposity acquired young is somehow less metabolically damaging per unit than adiposity acquired later. That is a real hypothesis, and this analysis does not establish it.

What it is good for

  • It answers a question people carry into the appointment. Long-standing obesity does not predict a worse response, on this evidence.
  • It is post hoc, splitting trials by a characteristic they were not designed around.
  • Age at diagnosis is self-reported and imprecise in a way that blurs the boundary between the groups.
  • Funded by Eli Lilly, which makes tirzepatide.

It also sits alongside two other findings on who responds. Rare genetic causes of obesity did not reduce response either (see genetics caused it and the drug still worked). And common genetic variants shift expected weight loss by well under a kilogram (see the genetics are real, and small).

Put together, the things people expect to predict a poor response mostly do not: how long you have had it, whether it runs in your family, whether there is a genetic cause. What does predict outcome, on the evidence in this corpus, is whether someone is still taking the drug a year later.

Frequently Asked Questions

On this evidence, yes. Across 3,782 participants in three trials, those whose obesity began before age 25 lost 23% of their body weight on tirzepatide against 22% for later onset, with similar improvements on every other measure.
No. The early-onset group had lived with obesity for twice as long, and had higher BMI and waist circumference but lower HbA1c, triglycerides and blood pressure.
The likeliest explanation is age. Someone whose obesity began before 25 is probably younger at enrollment, and younger people have better blood pressure and lipids regardless. The analysis does not state whether it adjusted for age.
Not duration, and not the genetic causes that have been examined. What predicts outcome most strongly in the available evidence is whether someone is still taking the drug a year later, and in real-world cohorts fewer than half are.
It is a post hoc split of trials not designed around age of onset, using self-reported diagnosis age, funded by the drug's manufacturer. The consistency across three separate trials is what makes it worth reporting.

References

  1. 1.Gourgari E, Srivastava G, Kelly AS, et al. Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials Obesity. 2025. PMID: 40717199.

A Trial About the Measuring Instrument

SAMARA will be reported as showing semaglutide improves fatty liver disease. It was built to ask whether non-invasive tests can replace a biopsy, and the drug was the tool used to answer it.

7 min read

Genetics Caused It, and the Drug Still Worked

MC4R mutations are the most common single genetic cause of obesity, and sit at the center of the brain's appetite pathway. Carriers in SURMOUNT-1 lost 18.3% of their weight against 19.9% in everyone else.

6 min read

The Genetics Are Real, and Small

A genome-wide study found genetic predictors of GLP-1 weight loss and side effects, at overwhelming significance. The efficacy effect is about three-quarters of a kilogram per copy.

8 min read

The Genetic Test That Isn't Ready

A paper titled 'GLP1R and OCT1 variants modulate semaglutide response' reports in its own results that the GLP1R signal did not survive correction, in an arm of ten. Carries a correction: larger work has since found real predictors.

5 min read

Rybelsus for Weight Loss: How Much Weight People Lose, and Why It's Less

Rybelsus is approved for type 2 diabetes, not weight. In its trials the 14 mg dose took off 3.1 to 4.4 kg in 26 weeks. Why the Wegovy pill does far more, what is known in people without diabetes, and why insurers won't cover it for weight.

10 min read

The Weight Comparison Used 257 People

A 30,458-patient study reported surgery producing 28.3% weight loss against 10.3% on GLP-1s, at lower two-year cost. The cost half uses the whole cohort. The weight half uses 1.6% of one arm.

7 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

Bodybuilding Health+

Seeing what it charges before you answer any medical questions

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →